Neurosurg Rev. 2025 Jul 17;48(1):571. doi: 10.1007/s10143-025-03726-4.
ABSTRACT
BACKGROUND AND PURPOSE: The Maurora stent (Drug eluting stent) is the first rapamycin-eluting vertebral artery stent system, and currently, there are no studies on the one-year outcomes of the Maurora stent in the treatment of severe vertebral artery ostium stenosis. Therefore, this study utilizes Cumulative sum (CUSUM) curve analysis to evaluate the one-year prognosis and restenosis rate of the Maurora stent in patients with severe stenosis at the vertebral artery origin.
METHODS: All patients were arranged in chronological order according to the sequence of their surgeries. CUSUM analysis was employed to assess the surgical learning curve. The point at which the CUSUM learning curve begins to descend marks the number of cases required to achieve procedural proficiency; this point delineates the transition from the initial stable phase to the mature phase. Postoperative Modified Rankin Scale(mRS) and NIHSS scores are visualized using histograms.
RESULTS: Ultimately, 38 patients met the inclusion and exclusion criteria and were included in the analysis. At the 1-year follow-up, 89.47% of patients had an MRS score of 0, showing a statistically significant improvement compared to preoperative values (p < 0.05). The MRS scores at 1year post-procedure showed a statistically significant difference between the mature and stable groups (P < 0.05).
CONCLUSIONS: The study showed that the Maurora stent (Drug eluting stent) is safe and effective in treating severe vertebral artery ostium stenosis, offering significant clinical value.
PMID:40673988 | DOI:10.1007/s10143-025-03726-4
